Skip to main content
. 2020 May 19;11(20):1799–1815. doi: 10.18632/oncotarget.27546

Figure 1. Entinostat upregulates the expression of activating and inhibitory human NK cell receptors.

Figure 1

(A) Effect of entinostat on NK cell-activating receptors, including DNAM, NKp46, NKG2D, and NKp80. The total percent receptor-positive of the CD3ε−CD56+ NK cells and their Mean Fluorescent Intensity (MFI) normalized to DMSO control are shown. (B) Effect of entinostat on NK cell inhibitory receptors including NKG2A, PD-1, KIR2DL1, KIR2DL2, KIR2DS4, KIR2DL5, and KIR3DL1. Data are shown as percent receptor-positive of the CD3ε−CD56+ NK cells and their MFI normalized to DMSO control are shown. Data shown in A and B are obtained by treating purified NK cells with or without entinostat from five to seven healthy donors per group. Data presented are the mean ± SD. Statistical significance was calculated using a ratio paired t-test. * p < 005; ** p < 0.01.